Amidst increasing popularity of semaglutide medications such as Wegovy and Ozempic, concerns have been raised that the glucagon-like peptide 1 receptor (GLP1R) agonist medications may increase suicidal thoughts. In a recent study, researchers analyzed electronic health records for 240,000 people being treated for excess weight or obesity with either semaglutide or a non-GLP1R medication. Treatment with semaglutide was associated with lower risk for suicidal ideation compared to non-GLP1R medications across demographic groups. Findings were replicated in 1.5 million people with type 2 diabetes being treated to lower blood pressure. To learn more, see the study in Nature.
